Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction - PubMed (original) (raw)
. 2001 Jun 28;411(6841):1058-64.
doi: 10.1038/35082583.
Affiliations
- PMID: 11429607
- DOI: 10.1038/35082583
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
A F Ochsenbein et al. Nature. 2001.
Erratum in
- Nature 2001 Sep 13;413(6852):183
Abstract
The vertebrate immune system has evolved to protect against infections that threaten survival before reproduction. Clinically manifest tumours mostly arise after the reproductive years and somatic mutations allow even otherwise antigenic tumours to evade the attention of the immune system. Moreover, the lack of immunological co-stimulatory molecules on solid tumours could result in T-cell tolerance; that is, the failure of T cells to respond. However, this may not generally apply. Here we report several important findings regarding the immune response to tumours, on the basis of studies of several tumour types. First, tumour-specific induction of protective cytotoxic T cells (CTLs) depends on sufficient tumour cells reaching secondary lymphatic organs early and for a long enough duration. Second, diffusely invading systemic tumours delete CTLs. Third, tumours that stay strictly outside secondary lymphatic organs, or that are within these organs but separated from T cells by barriers, are ignored by T cells but do not delete them. Fourth, co-stimulatory molecules on tumour cells do not influence CTL priming but enhance primed CTL responses in peripheral solid tumours. Last, cross priming of CTLs by tumour antigens, mediated by major histocompatibility complex (MHC) class I molecules of antigen-presenting host cells, is inefficient and not protective. These rules of T-cell induction and maintenance not only change previous views but also rationales for anti-tumour immunotherapy.
Comment in
- T cells and tumours.
Pardoll D. Pardoll D. Nature. 2001 Jun 28;411(6841):1010-2. doi: 10.1038/35082676. Nature. 2001. PMID: 11429587 No abstract available.
Similar articles
- Fibroblasts as efficient antigen-presenting cells in lymphoid organs.
Kündig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kühlcke K, Ohashi PS, Hengartner H, et al. Kündig TM, et al. Science. 1995 Jun 2;268(5215):1343-7. doi: 10.1126/science.7761853. Science. 1995. PMID: 7761853 - Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V, Schild HJ, Gückel B, von Hoegen P. Schirrmacher V, et al. Immunol Cell Biol. 1993 Aug;71 ( Pt 4):311-26. doi: 10.1038/icb.1993.36. Immunol Cell Biol. 1993. PMID: 7901150 - B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellström I, Hellström KE, Marquardt H, Chen L. Johnston JV, et al. J Exp Med. 1996 Mar 1;183(3):791-800. doi: 10.1084/jem.183.3.791. J Exp Med. 1996. PMID: 8642283 Free PMC article. - Principles of tumor immunosurveillance and implications for immunotherapy.
Ochsenbein AF. Ochsenbein AF. Cancer Gene Ther. 2002 Dec;9(12):1043-55. doi: 10.1038/sj.cgt.7700540. Cancer Gene Ther. 2002. PMID: 12522443 Review. - Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.
Melief CJ, Kast WM. Melief CJ, et al. Ciba Found Symp. 1994;187:97-104; discussion 104-12. doi: 10.1002/9780470514672.ch7. Ciba Found Symp. 1994. PMID: 7796678 Review.
Cited by
- The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies.
Jensen BA, Pedersen SR, Christensen JP, Thomsen AR. Jensen BA, et al. PLoS One. 2013 Jun 13;8(6):e66081. doi: 10.1371/journal.pone.0066081. Print 2013. PLoS One. 2013. PMID: 23785471 Free PMC article. - Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.
Adler AJ, Vella AT. Adler AJ, et al. Oncoimmunology. 2013 Jan 1;2(1):e22837. doi: 10.4161/onci.22837. Oncoimmunology. 2013. PMID: 23482891 Free PMC article. - Allogeneic beta-islet cells correct diabetes and resist immune rejection.
Pericin M, Althage A, Freigang S, Hengartner H, Rolland E, Dupraz P, Thorens B, Aebischer P, Zinkernagel RM. Pericin M, et al. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8203-6. doi: 10.1073/pnas.122241299. Proc Natl Acad Sci U S A. 2002. PMID: 12060765 Free PMC article. - Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location.
Kakinuma T, Nadiminti H, Lonsdorf AS, Murakami T, Perez BA, Kobayashi H, Finkelstein SE, Pothiawala G, Belkaid Y, Hwang ST. Kakinuma T, et al. Cancer Immunol Immunother. 2007 Jul;56(7):1119-31. doi: 10.1007/s00262-006-0253-4. Epub 2006 Dec 1. Cancer Immunol Immunother. 2007. PMID: 17139493 Free PMC article. - A sense of tumour for the immune system.
Todryk S. Todryk S. Immunology. 2002 Sep;107(1):1-4. doi: 10.1046/j.1365-2567.2002.01506.x. Immunology. 2002. PMID: 12225356 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials